PALO ALTO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Genencor International, Inc. today announced that the company will present at the 22nd Annual JP Morgan Healthcare Conference at 8:00 a.m. PST on Monday, January 12, 2004 at the Westin St. Francis Hotel in San Francisco, California. Jean-Jacques Bienaime, Genencor’s chairman, chief executive officer and president will report on the company’s health care strategy and progress in building a therapeutics pipeline. The current status of Genencor’s Hepatitis B vaccine and targeted cancer therapeutics programs will be discussed. In addition, Bienaime will review Genencor’s bioproducts business, including a report on the progress of its collaboration with the UK’s Health Protection Agency to develop a commercially viable technology to deactivate prions (agents that are associated with mad cow disease) on surgical instruments.
The live audio webcast of the presentation as well as the replay will be available at http://equityconferences.jpmorgan.com/ and the slide presentation may be accessed on the homepage at http://www.genencor.com/.
About Genencor
Genencor is a diversified biotechnology company that develops and delivers innovative products and services into the health care, agri-processing, industrial and consumer markets. Using an integrated set of technology platforms, Genencor’s products deliver innovative and sustainable solutions to many of the problems of everyday life.
Genencor traces its history to 1982 and has grown to become a leading biotechnology company, with over $350 million in year 2002 annual revenues. Genencor has principal offices in Palo Alto, California; Rochester, New York; and Leiden, the Netherlands.
Genencor International, Inc.
CONTACT: media, Valerie Tucker, +1-650-846-7500, or investors,Tom Rathjen, +1-650-846-7500, both of Genencor International, Inc.
Web site: http://www.genencor.com/
